Tirzepatide and gastric emptying in adults with T1D
What this study tests
A newly registered Lilly phase 1 study of how tirzepatide affects stomach emptying in adults with T1D and overweight or obesity. It uses acetaminophen absorption to assess gastric emptying; it is not a trial demonstrating improved long-term diabetes outcomes.
Editorial review: . What was checked and what remains uncertain.
Registry checked: 2026-09-16. Registry’s own update: 2026-09-04.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews.
Evidence at a glance
- Who can enter the study?
- Adults aged 18–70 with T1D treated with insulin for at least a year, BMI at least 25 kg/m² and stable weight. The registry lists a Miami site; it is not yet recruiting. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. The registry plans 18 participants, with estimated completion in December 2026. This pharmacology study cannot establish a general T1D treatment recommendation.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read this trial’s review notes for the checks completed and what remains unresolved. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Acetaminophen — Predose on Day 1 through 36 hours post dose
- PK: Area Under the Concentration Versus Time Curve from Time Zero to Time t (AUC0-tlast) of Acetaminophen — Predose on Day 1 through 36 hours post dose
- PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen — Predose on Day 1 through 36 hours post dose
The full picture
What the study asks
A newly registered Lilly phase 1 study of how tirzepatide affects stomach emptying in adults with T1D and overweight or obesity. It uses acetaminophen absorption to assess gastric emptying; it is not a trial demonstrating improved long-term diabetes outcomes.
Who it involves
Adults aged 18–70 with T1D treated with insulin for at least a year, BMI at least 25 kg/m² and stable weight. The registry lists a Miami site; it is not yet recruiting. This is a summary; the full registry lists additional criteria.1
Design and timing
The registry lists 18 participants (estimated enrollment). Primary completion: 2026-12 (estimated). Study completion: 2026-12 (estimated). Estimated dates can change and do not mean results are available.1
Evidence and limits
No results posted. The registry plans 18 participants, with estimated completion in December 2026. This pharmacology study cannot establish a general T1D treatment recommendation.
References
-
ClinicalTrials.gov. NCT07803744. Record checked 16 September 2026; last update posted 2026-09-04. https://clinicaltrials.gov/study/NCT07803744 ↩ ↩2
Sources
- [1]A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity (NCT07803744) · registry — Protocol and current registry status checked 16 September 2026.